⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

Official Title: Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy

Study ID: NCT02200081

Study Description

Brief Summary: Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Medizinische Universitaet Innsbruck, Innsbruck, , Austria

Universitair Ziekenhuis Gent, Gent, , Belgium

Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden Württemberg, Germany

Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain

Contact Details

Name: Veerle Surmont, MD

Affiliation: University Hospital Ghent, Belgium 9000

Role: PRINCIPAL_INVESTIGATOR

Name: Georg Pall, MD

Affiliation: Medizinische Universität Innsbruck, Innere Medizin, Hämatologie und Onkologie

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: